The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

BACKGROUND AND AIMS: Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Uschner, Frank Erhard, Schueller, Florian, Nikolova, Ivelina, Klein, Sabine, Schierwagen, Robert, Magdaleno, Fernando, Gröschl, Stefanie, Loosen, Sven, Ritz, Thomas, Roderburg, Christoph, Vucur, Michael, Kristiansen, Glen, Lammers, Twan, Luedde, Tom, Trebicka, Jonel
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6281422/
https://ncbi.nlm.nih.gov/pubmed/30546838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26333
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars